Bookmark

Add to MyYahoo RSS

SanofiSynthlabo News

News on SanofiSynthlabo (Ticker: SNY) continually updated from thousands of sources around the net.

Thursday | AmericanBankingNews.com

Sanofi SA (SNY) Announces Quarterly Earnings, Misses Expectations By $0.07 EPS

Sanofi SA issued its quarterly earnings data on Thursday. The company reported $0.72 earnings per share for the quarter, missing the consensus estimate of $0.79 by $0.07, ARN reports.

Comment?

Related Topix: Biotech, Semco Energy, Medicine, Genzyme General, Energy, Origin Healthcare Solutions, Acambis, Healthcare Industry

Wed Jul 30, 2014

Wall Street Journal

Sanofi Forecasts Profit Spurt

French drug maker Sanofi SA has raised its earnings outlook as it reported a jump in second-quarter profit on a strong showing by biotech unit Genzyme and stronger sales of its diabetes treatments.

Comment?

Related Topix: Biotech, Medicine, Genzyme General, Healthcare Industry, Origin Healthcare Solutions, Acambis, Opinion

Tue Jul 29, 2014

Reuters

Hungary launches probe against Sanofi-Aventis

Hungary's competition watchdog GVH has raided the Hungarian headquarters of French drug maker Sanofi-Aventis as the first step of a proceedings against the firm for a suspected abuse of its dominant market position, GVH said on Tuesday.

Comment?

Related Topix: Biotech

Sun Jul 27, 2014

She Knows

Top 10 most expensive corporate acquisitions

A native of the storied coastal city of Charleston, South Carolina, Julie Sprankles has been a lover of words her entire life.

Comment?

Related Topix: Best of 2007, Charleston, SC, Biotech, Cable & Satellite, Comcast, Pop/Rock

Tue Jul 15, 2014

The American Journal of Managed Care

Shifting to a Value-Based Approach

What is value and how do we define it? In a panel discussion led by moderator Jean-Paul Gagnon, former senior director, Sanofi-Aventis, participants were asked to analyze the ways in which healthcare can shift from a fee-for-service model to one that focuses on value.

Comment?

Related Topix: Biotech, Marketing

Fri Jul 11, 2014

AmericanBankingNews.com

Insider Buying: Sanofi SA major shareholder Buys 195,000 Shares of Stock

Sanofi SA major shareholder Sanofi bought 195,000 shares of the company's stock in a transaction dated Wednesday, July 9th.

Comment?

Related Topix: Biotech, Semco Energy, Medicine, Genzyme General, Energy, Origin Healthcare Solutions, Acambis, Healthcare Industry, Securities and Exchange Commission, Corporate / Securities Law, Law

AmericanBankingNews.com

Sanofi SA major shareholder Sanofi Buys 153,000 Shares

Sanofi SA major shareholder Sanofi purchased 153,000 shares of the stock in a transaction that occurred on Tuesday, July 8th.

Comment?

Related Topix: Biotech, Semco Energy, Medicine, Genzyme General, Energy, Origin Healthcare Solutions, Acambis, Healthcare Industry

Wed Jul 09, 2014

Insider Monkey

For Sanofi SA (ADR) (SNY) Chronic Diseases Present the Future Focus

In an interview with CNBC , Chris Viehbacher, the CEO of Sanofi SA , discussed the steps that big pharma companies like Sanofi SA are taking to tackle chronic diseases that are a major cause of worry for the aging baby boomers who are heading towards retirement age.

Comment?

Related Topix: Biotech, Semco Energy, Medicine, Genzyme General, Energy, Origin Healthcare Solutions, Acambis, Healthcare Industry, Family, Elderly (Senior Citizen)

Tue Jul 08, 2014

Reuters

Sanofi sues Eli Lilly over insulin rival to Lantus

Sanofi SA, whose top-selling Lantus helps diabetics control blood sugar levels, has filed a lawsuit accusing Eli Lilly and Co of infringing seven patents related to insulin and devices used to deliver it.

Comment?

Related Topix: Medicine, Lantus, Insulin Glargine (generic), Biotech, Insulin (generic), Humulin, Novolin, Eli Lilly, Healthcare Industry, Origin Healthcare Solutions, Acambis

The American Journal of Managed Care

Shifting to a Value-Based Approach

What is value and how do we define it? In a panel discussion led by moderator Jean-Paul Gagnon, former senior director, Sanofi-Aventis, participants were asked to analyze the ways in which healthcare can shift from a fee-for-service model to one that focuses on value.

Comment?

Related Topix: Biotech, Marketing

•••
•••
•••
•••
•••

Ashburn Jobs

•••
•••
•••
•••